Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer - Wikidata - wikimedia - TriplyDB

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

http://www.wikidata.org/entity/Q33847848

about

Capecitabine in the management of colorectal cancer Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.Age-specific cancer incidence rates increase through the oldest age groups.A case of long partial response to combination therapy of bevacizumab and capecitabine for liver metastases of rectal cancer Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer.Cost of care for colorectal cancer in Ireland: a health care payer perspective.Treatment of colorectal cancer in older patients.Systemic treatment of gastrointestinal cancer in elderly patients.The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

P2860

Q24633039-39C7D6A8-227F-42E1-985F-4CD4446FB1CC Q27002538-12B06DAC-D062-4274-9AA3-8F01041CE06D Q30244769-EFF736F7-34BC-4036-B41D-1E427E38E927 Q33918152-62AB09F5-A4E4-438D-86FE-32CD3B14542D Q33994078-F193E73D-AB6D-43C1-B3F1-43DED87F69A0 Q34569995-B8BFAC9D-609B-427D-AF7C-6B788BE76B46 Q34989562-5B4FBF57-88A6-494F-AB2D-32F3AC00BF4F Q35007200-95A76309-85B7-4A9C-AC81-70ADC1DF3398 Q35819857-A8CAC6DB-4E32-4C6A-B701-5DA7439E4FF2 Q37560960-907F0521-6B87-4306-87A1-33DECFEAD42B Q37884446-401594A2-E2C3-4A83-90E0-173E43377B55 Q38050375-F9A7F481-134D-4EF4-BBE2-F7F35FACA98A Q38059634-CD2B60C8-F954-4F2D-ABB4-2F78CAE0C88D Q38209147-B309CDB6-DCA1-4DD2-8F46-C18A95FFD9C7 Q38216008-B44F0EF0-8030-4583-ACF2-0C21E44F18F4 Q41231669-209706BD-FB08-460B-9EFF-1CE33CF8B921 Q42606229-9DADD275-0E88-4F39-901B-6E843137D37A Q44102658-42221883-0E70-4146-8B25-5483573A8E23 Q52657104-597127A7-542C-4C8E-A72C-17BFA9BA134B Q55385744-CD84F897-9CDD-414B-A5F0-406BA7366534

P2860

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

http://www.wikidata.org/entity/Q33847848

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@ast

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@en

type

label

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@ast

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@en

prefLabel

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@ast

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@en

P1433

Q33847848-279CBE2A-34E1-4439-BDDD-DC0C1350BBE1

P1476

Q33847848-92E112BD-3240-4179-964E-A8D01C895F5F

P2093

Q33847848-31EA72F5-CB72-4E51-8867-14C3A4AC61DD

Q33847848-4BCB3C98-51F7-4D03-9BE4-003660CEB06B

Q33847848-56C0D526-D6CA-4C02-A678-46DA21E5A0C9

Q33847848-6F288C1F-8468-460E-96BE-C2D12421CCB1

Q33847848-A33712BC-FF11-4C42-A33E-6AA3C60D0068

Q33847848-A3BD81D3-FA15-4A26-9B15-A9E7BA30E047

Q33847848-B218F42A-E1E9-4F0E-AED3-0AE49295EB81

Q33847848-B7A9E003-A408-47C9-96E5-2B461C7C5594

Q33847848-BB0B6A3B-CFBC-47FC-BA18-8E801F1A4ECE

Q33847848-C0AAB27D-A9DE-41B5-A3EE-5787C6DBA30E

P2860

Q33847848-06BA7B9A-EDE5-4D30-8D8A-E37E537D3990

Q33847848-0AF771E5-343E-4EE6-AEF6-29F5A8950725

Q33847848-12CDF4A9-0A64-4D77-B7A3-D9E8DD7524A7

Q33847848-13E6843C-E96B-49D7-B03D-81F9EC1FEE1B

Q33847848-35B2FAF1-E059-42CE-BB7B-B5AE99A53B7B

Q33847848-4DCD640E-DD95-4DE3-8348-25F7BE4FE76E

Q33847848-516173A9-5435-41F6-8D94-AF1F935BB80C

Q33847848-5D6D8816-C395-46E9-A850-2C58B596C639

Q33847848-6253869E-F5CF-4437-82CA-91353424761C

Q33847848-64F2617A-C1D1-4A99-AF82-5D8FD59DEB45

P2888

Q33847848-F16ED486-E9C5-4ABE-BE3C-5042D2EEFB25

P304

Q33847848-B25D036D-03A9-438C-934F-FBC765D9EC36

P31

Q33847848-5E70DA52-99F5-4472-AB12-1F9A11988AA5

P356

Q33847848-4EB4E561-8804-41CB-816A-A08E1F5662FF

P407

Q33847848-7439FCAD-E7DE-47BC-8CBA-B45EBBBF902E

P433

Q33847848-ED6184BD-A6E7-4CF3-85CA-39C711C05656

P478

Q33847848-6E50DFEC-5041-41D6-956A-66B60AD9605B

P50

Q33847848-BA1FA1EF-0CD0-4F63-ADB9-36D39F02F7DE

P577

Q33847848-DC2A1343-CCFA-4CE2-97F3-63C006DBFFC8

P5875

Q33847848-E640FBBB-4EBA-435E-8679-39F84E86C1AE

P6179

Q33847848-592B95B9-D741-4FFD-855D-50050C5BA1EF

P698

Q33847848-4F6CE610-4B3A-4B1F-8176-B7E41DC1A236

P921

Q33847848-0057FAFB-98E1-45E0-A84C-9B8C3BFDC710

Q33847848-1FB458CF-3D9D-4579-AFEA-2C5975D49411

P932

Q33847848-2AA82E33-7C07-4524-A068-4AFB2D0FC984

P356

P1433

British Journal of Cancer

P1476

Capecitabine and bevacizumab a ...... h metastatic colorectal cancer

@en

P2093

A Llombart

http://www.w3.org/2001/XMLSchema#string

C Bosch

http://www.w3.org/2001/XMLSchema#string

C García-Girón

http://www.w3.org/2001/XMLSchema#string

C Madroñal

http://www.w3.org/2001/XMLSchema#string

F Losa

http://www.w3.org/2001/XMLSchema#string

J Castro-Carpeño

http://www.w3.org/2001/XMLSchema#string

J Feliu

http://www.w3.org/2001/XMLSchema#string

M Bolaños

http://www.w3.org/2001/XMLSchema#string

M Gil

http://www.w3.org/2001/XMLSchema#string

M González-Barón

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Prediction of creatinine clearance from serum creatinine

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

P2888

P304

1468-1473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605663

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348753

http://www.w3.org/2001/XMLSchema#string

P6179

1050400680

http://www.w3.org/2001/XMLSchema#string

P698

20424611

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2869164

http://www.w3.org/2001/XMLSchema#string